Spectrum Pharma (SPPI) Tops Q2 EPS by 24c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Spectrum Pharmaceuticals Reports Second Quarter 2016 Financial Results and Pipeline Update
August 9, 2016 4:00 PM EDTSPI-2012 (eflapegrastim) pivotal Phase 3 study is actively enrolling breast cancer patients in over 80 clinical sites in the U.S. Poziotinib Phase 2 trial is enrolling breast cancer patients who have failed other HER2-directed therapies. Qapzola (apaziquone) advisory panel scheduled on September 14, 2016, and FDA decision expected on December 11, 2016. Q2 revenues were $33.9 million, including $30.9 million in product sales. The Companys sixth FDA approved drug EVOMELA® (melphalan) for injection was launched in the second quarter; formulary access and adoption in top institutions is encouraging. The... More
